

Available online on 22.08.2019 at <http://jddtonline.info>

# Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited



Open Access

Review Article

## Review on Teneligliptin: A novel antihyperglycemic agent

V. D. Gorde<sup>1\*</sup> Dr. Punit R. Rachh<sup>2</sup><sup>1</sup> Research scholar, Department of pharmaceutical science, Bhagwant University, Ajmer, Rajasthan.<sup>2</sup> Department of pharmaceutical science, Bhagwant University, Ajmer, Rajasthan.

### ABSTRACT

Diabetes mellitus relates a metabolic disorder of collective aetiology which is characterized by chronic hyperglycaemia caused due to disturbances of carbohydrate, lipid and protein metabolism due to impaired  $\beta$  cell function of pancreas or insulin resistance or both. Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged as a new class of antidiabetic that show favorable results in improving glycemic control with a minimal risk of hypoglycemia and weight gain. Teneligliptin is a recently developed oral dipeptidyl peptidase 4 inhibitor indicated for the management of type 2 diabetes mellitus. Teneligliptin, characterized by a "J-shaped" structure formed by five consecutive rings which give unique binding characteristics, reflect in higher potency than other dipeptidyl peptidase 4 inhibitor. Teneligliptin is a novel antihyperglycemic agent with a preferable profile in terms of long-term efficacy and safety in patients with type 2 diabetes.

**Keywords:** Diabetes Mellitus, Dipeptidyl Peptidase 4 Inhibitor, Teneligliptin, Hypoglycemia,

**Article Info:** Received 11 June 2019; Review Completed 25 July 2019; Accepted 02 August 2019; Available online 22 August 2019



### Cite this article as:

Gorde VD, Rachh PR, Review on Teneligliptin: A novel antihyperglycemic agent, Journal of Drug Delivery and Therapeutics. 2019; 9(4-s):742-747 <http://dx.doi.org/10.22270/jddt.v9i4-s.3275>

### \*Address for Correspondence:

V. D. Gorde, Research scholar, Department of pharmaceutical science, Bhagwant University, Ajmer, Rajasthan.

### Introduction:

Diabetes mellitus (DM) is probably one of the oldest diseases known to man. Diabetes is the increasingly growing metabolic threat of our contemporary era. Diabetes was first described in an Egyptian manuscript from 1500 BC, mentioning "too great emptying of the urine". Later on, Indian physicians described the disease and classified it as honey urine by the fact that ants were attracted by patient's urine. The term "diabetes" or "to pass through" was first used in 250 BC by the Greek Apollonius of Memphis<sup>1</sup>. There were more than 73 million cases of diabetes in India in 2017<sup>2</sup> and achieved undesired title 'centre for diabetes in world' with millions populations and many more rising<sup>3</sup>.

Complications of diabetes are a major cause leading to morbidity and mortality in India and type 2 diabetes mellitus (T2DM) is thus considered as one of the major growing epidemics<sup>4, 5</sup>. Diabetes affects many organs, and complications due to high blood glucose are an important cause of disability, reduced quality of life, and premature death<sup>6</sup>. For the proper management of the disorder, the medicament has to be taken at regular intervals of time, lifelong. Conventional antidiabetic oral dosage forms offer no control over drug delivery, leading to fluctuations in plasma drug concentration and causes irregular glucose level in the patient's body. This shows that there are most requirements

of the antidiabetic drugs to maintain the blood glucose level over the extended period of time for better therapeutic efficacy of drug.

Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged as a new class of antidiabetic that show favorable results in improving glycemic control with minimal risk Type 2 diabetes mellitus complications. Teneligliptin is a novel oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM) having a unique structure characterized by five consecutive rings, which produce a potent and long-lasting effect<sup>7</sup>. Teneligliptin is currently used in cases showing insufficient improvement in glycemic control even after diet control and exercise or a combination of diet control, exercise, and oral hypoglycemic drugs used include Biguanides, Sulphonylureas<sup>8, 9</sup>.

Teneligliptin was originally synthesized by Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) and was the first drug of its kind to be synthesized in Japan. Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co, Ltd, (Tokyo, Japan)

### The economic costs of T2DM<sup>10</sup>

There is a substantial economic impact of diabetes on individuals, society, health care system, employer, and even the country in terms of loss of productivity. Reported

evidence suggests that there is a strong and direct economic impact of T2DM on the lives of people in lower income settings. In developing countries, where health care expenditure is many times out-of-pocket, an economic impact of T2DM is huge and may affect the long-term outcome of T2DM. There should be affordable medical treatment available to all. The cost of medicine should not be a barrier for health care. In this scenario, availability of economical DPP-4 inhibitors such as teneligliptin is a positive step.

### Role of Teneligliptin in Type-2 Diabetes Mellitus therapy

Dipeptidyl peptidase-4 (DPP-4) work by increasing levels of active glucagon-like peptide-1 (GLP-1), thereby promoting insulin secretion, in a blood glucose-dependent manner, and hence decreasing glucose levels while minimizing the risk of hypoglycaemia. DPP-4 inhibitors are recommended in international guidelines<sup>11</sup>. Meta-analyses have suggested that DPP-4 inhibitors may be more potent in reducing HbA1c levels in Asian T2DM patients than in non-Asian patients<sup>12,13</sup>. Published evidence suggests that even 1% reduction in

HbA1c reported significant reduction in the risk of long-term complications associated with T2DM<sup>14</sup>.

Incretin hormones, namely glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released from enteroendocrine cells and enhance insulin secretion<sup>15, 16</sup>. Incretins are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), and have a very short half-life ( $t_{1/2}$ ) as a result. DPP-4 inhibitors increase the levels of active GLP-1 and GIP by inhibiting DPP-4 enzymatic activity; thus, in patients with diabetes, these inhibitors improve hyperglycemia in a glucose-dependent manner by increasing serum insulin levels and decreasing serum glucagon levels<sup>15, 17</sup>. Therefore, incretin-related agents such as DPP-4 inhibitors are promising drugs that can decrease glucose fluctuations in diabetic patients and have emerged as a new class of antidiabetic. Rise in new beta-cells and inhibition of their apoptosis is seen with Dipeptidyl peptidase-4 (DPP-4) which can potentially improve the disease pathogenesis. The American Diabetes Association (ADA) guidelines recommend Dipeptidyl peptidase-4 (DPP-4) as second-line therapy after metformin. Therefore, DPP-4 can be the choice of drugs in every T2D patient<sup>18</sup>.




Figure 1: Structural heterogeneity of dipeptidyl peptidase-4 (DPP-4) inhibitors.




Figure 2: Chemical structure of teneligliptin.

## Chemistry of Tenueligliptin<sup>19,20</sup>

Despite their common mechanism of action, DPP-4 inhibitors show marked structural heterogeneity (Figure 1). DPP-4 inhibitors may be classified into peptidomimetic (i.e., sitagliptin, vildagliptin, saxagliptin, and anagliptin) and non-peptidomimetic (i.e., alogliptin and linagliptin) subtypes. Tenueligliptin, {(2S, 4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl) piperazin-1-yl] pyrrolidin-2-yl} (1, 3-thiazolidin-3-yl) methanone hemipentahydrobromide hydrate exhibits a unique structure that is characterized by five consecutive rings (Figure 2) and is peptidomimetic. An X-ray co-crystal structure of tenueligliptin with DPP-4 demonstrates that the key interaction occurs between the phenyl ring on the pyrazole and the S2 extensive subsite of DPP-4, which not only enhances the potency of the drug but also increases its selectivity.

## Pharmacokinetic and pharmacodynamic properties of Tenueligliptin<sup>21</sup>

The plasma concentrations of tenueligliptin after the administration of tenueligliptin at dosages of 10 or 20 mg once daily for 4 weeks revealed a median time to maximum concentration (C<sub>max</sub>) of 1.0 hour in both groups and a mean t<sub>1/2</sub> of 20.8 and 18.9 hours, respectively. The maximum percentage of the inhibition in plasma DPP-4 activity was achieved within 2 hours after administration and was 81.3% and 89.7% in the 10 and 20 mg tenueligliptin groups, respectively. A pharmacokinetic/pharmacodynamic study revealed that tenueligliptin inhibits DPP IV activity over 24 hours, with elevation of activated glucagon-like peptide 1 (GLP-1) levels and the resulting suppression of postprandial hyperglycemia at all three daily meals. Monotherapy for 12 weeks significantly decreased hemoglobin A1c (HbA1c), fasting blood glucose, and 2-hour postprandial blood glucose levels in patients with type 2 diabetes. The therapeutic

efficacy of tenueligliptin over 52 weeks was confirmed not only as monotherapy but also as add-on therapy in patients with inadequately controlled blood glucose levels with sulfonylureas or thiazolidinediones.

## Metabolism and excretion of Tenueligliptin<sup>22</sup>

Tenueligliptin has dual mode of excretion *i.e.*, hepatic and renal routes. About 34.4% of tenueligliptin is excreted unchanged via the kidney and the remaining 65.6% tenueligliptin is metabolized and eliminated via renal and hepatic excretion; 216 hours after the administration of <sup>14</sup>C-labeled tenueligliptin (20 mg), the cumulative excretion percentages of radioactive tenueligliptin in urine and feces were 45.4% and 46.5%, respectively. Tenueligliptin is eliminated via excretion with a half-life of 24.2 hours in human plasma from the kidney and metabolism involving certain enzymes.

## Tenueligliptin - Stronger DPP- 4 Inhibitor than other DPP- 4 Inhibitor<sup>7,22,23</sup>

Tenueligliptin might have stronger inhibitory action against DPP-4 than other DPP- 4 inhibitors, because the plasma DPP-4 activity was significantly decreased after switching to tenueligliptin. Tenueligliptin has a unique structure, and binds to the S1, S2 and S2 extensive subsite of the DPP-4 enzyme, leading to enhanced potency and selectivity, and it is also a class 3 DPP-4 inhibitor. Additionally, binding of tenueligliptin to the S2 extensive site, apart from the S1 and S2 sites, imparts stronger inhibitory action on the DPP-4 enzyme. Furthermore, tenueligliptin was reported to have the J-shaped anchor-lock domain, strong covalent bonds with DPP-4 and more extensive S2 extensive binding, showing its higher inhibitory activity.

**Table 1 Summary of the interactions of various DPP-4 inhibitors with DPP-4 enzyme<sup>19, 22, 24, 25</sup>**

Class	DPP-4 inhibitors	Binding at DPP-4	Details
I	Vildagliptin and saxagliptin	S1 and S2 subsites	<ul style="list-style-type: none"> <li>• Most fundamental level of interaction</li> <li>• Cyanopyrrolidine moieties bind with S1</li> <li>• Hydroxy adamantyl group binds with S2</li> <li>• Saxagliptin has fivefold higher activity than vildagliptin</li> </ul>
II	Alogliptin and linagliptin	S1, S2, S1', and S2' subsites	<ul style="list-style-type: none"> <li>• Additional binding to S1' and S2'</li> <li>• Alogliptin binds to S1, S2, and S1'</li> <li>• Linagliptin binds to S1, S2, S1', and S2'</li> <li>• Linagliptin had eightfold higher activity than alogliptin</li> </ul>
III	Sitagliptin and tenueligliptin	S1, S2, and S2 extensive subsites	<ul style="list-style-type: none"> <li>• Binds S1, S2, and S2 extensive</li> <li>• Tenueligliptin has fivefold higher activity than sitagliptin, because of: <ul style="list-style-type: none"> <li>• Tenueligliptin has favorable (J-shaped) structure leading to small loss of energy during binding with DPP-4</li> <li>• Tenueligliptin forms hydrogen bond with DPP-4</li> <li>• Tenueligliptin has more extensive binding at "S2 extensive" site than sitagliptin</li> </ul> </li> </ul>

A crystallographic study suggested that the key interaction between a phenyl ring on teneligliptin and the S2 extensive subsite of DPP-4 enhances the drug's potency and may increase its selectivity<sup>12</sup>. Teneligliptin differs from other clinically used DPP-4 inhibitors, including sitagliptin, with regard to its elimination pathway. With teneligliptin, this involves both hepatic and renal excretion; whereas other DPP-4 inhibitors are typically eliminated by renal excretion only<sup>13</sup>. This may reflect the potency of teneligliptin as an inhibitor of DPP-4, based on its unique binding characteristics derived from its chemical structure.

### Teneligliptin in the Management of T2DM complications:

In adults, 20 mg of teneligliptin may be orally administered once daily. If this dosage is insufficient, the dosage is increased to 40 mg once daily.

#### Effect of Teneligliptin on blood glucose level<sup>26, 27</sup>

Treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors, which are incretin-related antidiabetic agents, is widely accepted in clinical practice because of their low risk of hypoglycemia and their beneficial effect on glucose control. To assess blood glucose control over 24 hours and the safety of teneligliptin at 10 and 20 mg doses, a randomized, double-blind, placebo-controlled, parallel-group study was conducted at four locations in Japan, results indicate that the once-daily administration of teneligliptin before breakfast improved blood glucose control, even at dinnertime.

#### Effect of Teneligliptin on insulin<sup>7, 28</sup>

Patients with T2DM receiving insulin therapy, with or without other antidiabetic agents, the addition of teneligliptin reported significant improvement in diurnal glycemic control and significant reductions in glucose fluctuations in 24-hour periods without increasing the risk of hypoglycaemia.

#### Effect of Teneligliptin on glucagon<sup>7</sup>

The postprandial glucagon levels significantly decreased after breakfast and lunch as well as after dinner in the teneligliptin-treated group compared with the corresponding values in the placebo group.

### Renoprotection of Teneligliptin in type 2 diabetes patients with diabetic kidney disease<sup>23, 29 - 33</sup>

Diabetic kidney disease (DKD), which is a diabetic vascular complication, is recognized as a major leading cause of end stage renal disease. Glucose control is fundamentally important for the prevention of DKD, as well as the control of blood pressure (BP) using renin-angiotensin system (RAS) inhibitors. However, hypoglycemia should be avoided, because hypoglycemia is closely related to increased mortality, which is associated with an increased incidence of cardiovascular disease. In addition to their glucose-lowering effect, DPP-4 inhibitors have renoprotective effects, which are mainly a reduction in albuminuria, independent of the glucose-lowering effect. Teneligliptin has strong and long DPP-4 inhibitory effects, and no dose adjustment may be required, even if the patient has renal function decline. Because 34.4% of the administered dose of teneligliptin is excreted unchanged through the renal route, whereas 65.6% is metabolized and eliminated through the hepatic and renal routes. In addition, the distribution of teneligliptin to the kidney is high because of its lipophilicity, possibly showing a renoprotective effect. DPP-4 inhibitors exerted their renoprotective effect through anti-inflammation, antioxidative stress and anti-fibrosis.

### Effects of Teneligliptin on lipid profiles<sup>34 - 38</sup>

The lipid profile is an important determinant of cardiovascular risk in type 2 diabetes. It can affect antidiabetic therapy and is important in the clinical management of patients with type 2 diabetes. A potential beneficial effect of DPP-4 inhibitors on cholesterol, which could contribute to a reduction in cardiovascular risk. The administration of several DPP-4 inhibitors reduces postprandial triglyceride levels in humans, mice, and hamsters.

### Gliptins in combination with other oral antidiabetic agents<sup>39 - 42</sup>

Since DPP-4 inhibitors and metformin improve glycemic control via different, albeit potentially complementary, mechanisms, combination therapy with these two agents should provide effective and potentially additive glycemic control. Studies using combination therapy of DPP-4 inhibitors and metformin (as one pill) showed favorable results in glycemic control because of favorable pharmacokinetic characteristics and complementary pharmacodynamic effects, which include enhanced incretin effect, suppressed hepatic glucose production, and improved peripheral insulin sensitivity. Moreover, in general, the combination of this drug into a single tablet improves patients' compliance and often results in a lower cost of treatment.

### Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury<sup>43 - 46</sup>

Cardiovascular complications are the main causes of mortality in diabetic patients. Teneligliptin is a newly developed anti-diabetic agent. It has been reported that teneligliptin has a vascular protective capacity in preclinical studies and diabetes patient. The prevalence of diabetes mellitus has been a major threat to human health worldwide. The high prevalence of diabetes has increased the risk of serious diabetes-related complications. Diabetes-associated vascular diseases affect nearly all blood vessel types and sizes including arteries, veins and microvasculature. The long-time burden of diabetes often causes cardiovascular complications and ultimately, cardiovascular disease. Epidemiological data have shown that patients with type 2 diabetes mellitus have a considerable two to four fold higher risk of cardiovascular morbidity and mortality as compared with the non-diabetes population. It has been recognized that vascular complications are the cause of most morbidities, hospitalizations, and mortalities in diabetes patients. Curing cardiovascular complications and lowering glucose are the goals for an effective treatment for type 2 diabetes. Gliptins are a class of glucose-lowering agents for the treatment of type 2 diabetes. Recently, several kinds of gliptins have been shown to be effective in improving endothelial function, reducing oxidative and pro-inflammatory states, and exerting beneficial effects on cardiovascular function. Teneligliptin is one of the newly approved gliptins and has been shown to be effective in treating type 2 diabetes. Interestingly, teneligliptin has displayed various cellular effects that are associated with vascular protection. It has been shown that teneligliptin can improve cardiac remodeling in hypertensive rats and improve endothelial dysfunction in prediabetic rats. A recent study demonstrated that teneligliptin inhibits atherogenesis in mice. In human subjects, administration of teneligliptin in diabetes patients improves patients' endothelial function and heart function. Teneligliptin also regulates platelet-derived microparticles, suggesting that it possesses an anti-atherothrombotic effect

in patients with type 2 diabetes. Taken together, teneligliptin appears to be a very appealing anti-diabetic agent with the potent dual effects of reducing glucose and vascular protection. This versatile functional profile indicates that teneligliptin is a very promising drug for the control of diabetes as well as its vascular complications.

### The neurovascular protective effect of gliptin in murine MCAO model and brain endothelial cells<sup>47, 48</sup>

Gliptins are a novel class of treatment agents for diabetes, and recent studies have linked the use of gliptins to neuroprotection. Recently, studies have suggested that administration of gliptins could exert neuroprotective effects in mice. A meta-analysis that included more than 9000 human subjects concluded that gliptins may have certain protective effects in stroke condition.

### DPP-4 Inhibitors and Patient Weight<sup>49-52</sup>

Studies on the influence of DPP-4 inhibitors on patient weight demonstrated variable results but are generally considered to be neutral.

### The Novel Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Prevents High-Fat Diet-Induced Obesity Accompanied With Increased Energy Expenditure in Mice<sup>53</sup>

Dipeptidyl peptidase-4 (DPP-4)-deficient mice exhibit prevention of obesity with increased energy expenditure. The novel DPP-4 inhibitor teneligliptin prevents obesity and obesity-related manifestations with increased energy expenditure.

### Conclusion

All major guidelines recommend metformin as the first-line treatment in patients with diabetes. The American Diabetes Association (ADA) guidelines recommend dipeptidyl peptidase-4 as second-line therapy after metformin. Therefore, dipeptidyl peptidase-4 can be the choice of drugs in every T2D patient. Despite their common mechanism of action, DPP-4 inhibitors show marked structural, pharmacokinetic and pharmacodynamic heterogeneity. Teneligliptin differs from other clinically used DPP-4 inhibitors. Teneligliptin has a unique structure and binding site leading to enhanced potency and selectivity, imparts stronger inhibitory action on the DPP-4 enzyme.

### References

- Brian C, Leutholtz, Ripoll I. Exercise and disease management. 2nd ed. CRC Press, 2011: 256 Pages - 9 B/W Illustrations 2
- Poretzky L. Principles of diabetes mellitus. 2nd ed. New York: Springer, 2009
- Available from: <https://www.idf.org/ournetwork/regions-members/south-east-Asia/members/94-india.html>.
- Kaveeshwar, S. A., & Cornwall, J. (2014). The current state of diabetes mellitus in India. *The Australasian medical journal*, 7(1), 45.
- India NCD Country Profile 2014. World Health Organization (2014). Non communicable Diseases Country Profiles 2014.
- Shetty, P. (2012). Public health: India's diabetes time bomb, *Nature*, Vol. 485, pp. 14-16. (Currently facing an uncertain future imposing potential burden to the country. As per the Indian scenario, the prevalence of diabetes in 2013 was 9.1% vs. 8.3% worldwide which is slightly higher in India (International Diabetes Federation, 2014). A report says that 60% of death in 2012 is due to non-communicable diseases say cardiovascular disease, respiratory disease, diabetes, cancer etc. (World Health Organization (2014).
- IDF. *IDF Diabetes Atlas, 7th Edn*. Brussels, Belgium: International Diabetes Federation; 2015.

- Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. *Diabetes Metab Syndr Obes*. 2013; 6:187-195.
- Walker R and Whittlesia C: Clinical pharmacy and therapeutics, Willstone church, Elsevier 2000, 685-710.
- Ibrahim R: Diabetes Mellitus Type II: Review of Oral Treatment Options. *International Journal of Pharmacy and Pharmaceutical Sciences* 2010; 2(1): 21-30.
- Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. *Pharmacoeconomics*. 2015; 33(8):811-831.
- American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2018. *Diabetes Care*. 2018; 41(suppl 1):S73-S85.
- Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. *Ann Pharmacother*. 2012; 46:1453-1469.
- Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. *Diabetologia*. 2013; 56:696-708.
- Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000; 321:405-412.
- Drucker DJ. The role of gut hormones in glucose homeostasis. *J Clin Invest*. 2007; 117:24-32.
- Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. *Curr Diab Rep*. 2006; 6:194-201.
- Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. *Diabetes Obes Metab*. 2007; 9:186-193.
- American Diabetes Association. Standards of Medical Care in Diabetes. *Diabetes Care*. 2017; 40:S64-S74.
- Yoshida T, Akahoshi F, Sakashita H, et al. Discovery and preclinical profile of teneligliptin(3-[[[2S,4S]-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazinyl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. *Bioorg Med Chem*. 2012; 20:5705-5719.
- Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. *Drugs*. 2011; 71:1441-1467.
- Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. *Drugs Today (Barc)*. 2013 Oct; 49(10):615-29. doi: 10.1358/dot.2013.49.10.2035882.
- Nabeno M, Akahoshi F and Kishida: A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. *Biochem Biophys Res Commun*. 2013; 434: 191-196.
- Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P and Swami OC: Teneligliptin in management of type 2 diabetes mellitus, diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal 2016; 9: 251-260.
- Chen XW, He ZX, Zhou ZW, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. *Clin Exp Pharmacol Physiol*. 2015;42(10):999-1024.
- Kushwaha RN, Haq W, Katti SB. Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes: a synthetic overview. *Chem Biol Interface*. 2014;4(3):137-162.
- Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. *Diabetes Obes Metab*. 2012; 14:1040-1046.
- Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. *Cleve Clin J Med* 2009; 76(Suppl. 5):S28-S38
- Tanaka S, Suzuki K, Aoki C, et al. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. *Diabetes Technol Ther*. 2014;16(12):840-845.

29. Abubaker M, Mishra P, Swami OC. Tenelegliptin in management of diabetic kidney disease: a review of place in therapy. *J Clin Diagn* 2017; 11: OE05–OE09.
30. Howse PM, Chibrikova LN, Twells LK, et al. Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: a systematic review and metaanalysis. *Am J Kidney Dis* 2016; 68: 733–742
31. Halabi A, Maatouk H, Siegler KE, Faisst N, Luft V, Klause N. Pharmacokinetics of tenelegliptin in subjects with renal impairment. *Clin Pharmacol Drug Dev.* 2013;2(3):246–254.
32. Otsuki H, Kosaka T, Nakamura K, Shimomura F, Kuwahara Y, Tsukamoto T. Safety and efficacy of tenelegliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. *Int Urol Nephrol.* 2014; 46(2):427–432.
33. Tanaka K, Okada Y, Mori H, et al. Efficacy of linagliptin and tenelegliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study. *Diabetol Int.* 2016:1–7. Available from: <http://link.springer.com/article/10.1007%2Fs13340-016-0258-y>.
34. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. *Drugs.* 2011; 71:1441–1467.
35. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. *Adv Ther.* 2012; 29:14–25. 25. Poitout V, Robertson RP. Glucolipototoxicity: fuel excess and beta-cell dysfunction. *Endocrine Rev.* 2008; 29:351–366.
36. Sone H, Tanaka S, Tanaka S, et al; Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). *J Clin Endocrinol Metab.* 2011; 96:3448–3456.
37. Matikainen N, Mänttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. *Diabetologia* 2006;49:2049–2057
38. Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. *J Clin Endocrinol Metab* 2009;94:846–852
39. Koliaki C, Doupis J. Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology. *Adv Ther.* 2012; 29(12):993–1004.
40. Genovese S, Tedeschi D. Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization. *Adv Ther.* 2013; 30(2):152–164.
41. Dicker D. DPP-4 inhibitors. Impact on glycemic control and cardiovascular risk factors. *Diabetes Care.* 2011; 34Suppl 2:S276–S278.
42. Kim MK, Rhee EJ, Han KA, et al. Efficacy and safety of tenelegliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, doubleblind, placebo-controlled phase III trial. *Diabetes Obes Metab.* 2015; 17(3): 309–312.
43. H. Abe, H. Semba, N. Takeda, The roles of hypoxia signaling in the pathogenesis of cardiovascular diseases, *J. Atheroscler. Thromb.* 24 (9) (2017) 884–894.
44. V. Gupta, S. Kalra, Choosing a gliptin, *Indian J. Endocrinol. Metab.* 15 (4) (2011) 298–308.
45. F. Remm, W.M. Franz, C. Brenner, Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease, *Eur. Heart J. Cardiovasc. Pharmacother.* 2 (3) (2016) 185–193.
46. A. Avogaro, S. de Kreutzenberg, and G. Fadini, Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection, *Curr. Pharm. Des.* 20 (14) (2014) 2387–2394.
47. V. Darsalia, M. Larsson, G. Lietzau, D. Nathanson, T. Nyström, T. Klein, C. Patrone, Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor, *Diabetes Obes. Metab.* 18 (5) (2016) 537–541.
48. F. Barkas, M. Elisaf, V. Tsimihodimos, H. Milionis, Dipeptidyl peptidase-4 inhibitors and protection against stroke: a systematic review and meta-analysis, *Diabetes Metab.* 43 (1) (2017) 1–8.
49. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. *JAMA* 2007;298:194–206
50. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2007;30:1979–1987
51. Scheen AJ. A review of gliptins in 2011. *Expert Opin Pharmacother.* 2012; 13:81–99.
52. Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. *Curr Med Res Opin.* 2007; 23:1493–1507.
53. Sayaka Fukuda-Tsuru, Tetsuhiro Kakimoto, Hiroyuki Utsumi, Satoko Kiuchi, Shinichi Ishii, The novel dipeptidyl peptidase-4 inhibitor tenelegliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice, *European Journal of Pharmacology* Volume 723, 15 January 2014, Pages 207-215